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RESULTS

BACKGROUND
pproximately 13-26% of all acute ischemic strokes are related
to atrial fibrillation (AF) and are associated with increased risk of
systemic embolism and death. Anticoagulants (AC) are
recommended after an ischemic stroke or transient ischemic
attack (TIA) secondary to AF; however, the main challenge in
current practice is determining the appropriate time of initiation.
There is increased risk of both recurrent ischemic stroke and
hemorrhagic transformation (HT) within the first two weeks
following a primary stroke. According to the American Heart
Association/American College of Cardiology (AHA/ACC) Atrial
fibrillation guidelines, AC initiation is recommended between 414 days after event. Factors contributing to the risk of HT include
use of thrombolytics or AC, baseline infarct size, presence of
microhemorrhages, and mechanical thrombectomy procedure.
This retrospective study will review patients with AF who
subsequently developed an ischemic stroke or TIA. Time of AC
initiation, use of thrombolytics, in-patient recurrent stroke or HT,
and appropriateness of AC utilization will be reviewed.

A

Patient Characteristics
Demographics
Median age, years (range)
Gender—female, n (%)
Race
Hispanic, n (%)
Whites, n (%)
African American, n (%)
Median length of stay, days (range)
AC prescribed prior to admission, n (%)
Stroke classification—ischemic, n (%)

DISCUSSION
• 61% of patient were started on AC during hospital course
• Median time to AC initiation in ischemic stroke /TIA was 3 days
• Initiation of AC therapy was planned and/or deferred to postdischarge in 39% of the patients
• Overall, 97% of the patients who were initiated AC therapy received it
within 14 days (39% within 4-14 and 58% within 0-4 days)
• Average time to AC in patients who received thrombolytic therapy,
underwent thrombectomy, or had a combination of both, was ~5 days
• In-patient symptomatic HT occurred in 3 patients, their average NIHSS
score on admission was 11
• There was an 11% increase in the number of patients receiving
appropriate AC upon discharge when compared to admission
• Factors contributing to delayed or deferred AC therapy included
occurrence of HT, increased bleeding risk, or surgical procedures
• Reasons for inappropriate AC on admission or discharge were
incorrect dose and noncompliance to recommended therapy

N = 96
81 (54-89)
50 (52)

50 (52)
34 (35)
11 (11)
6 (1-89)
39 (41)
87 (91)

Primary Outcomes
Median time to AC initiation, days (range)

3 (0.21-32)

LIMITATIONS
•
•
•
•

PURPOSE
To assess the timing of AC initiation in patients presenting with
ischemic stroke or TIA due to AF, and to determine potential
areas for improvement to facilitate safe and effective use.

CONCLUSION

METHODS
• Single-center, retrospective chart review
o Deemed as a performance improvement initiative per
the BHSF IRB
• Inclusion criteria:
o Hospitalized adult patients > 18 years of age
o Acute ischemic stroke or TIA
o Known or new-onset AF
o Received AC
• Exclusion criteria:
o Contraindication to AC (e.g. ongoing bleeding,
mechanical heart valve prosthesis, HT)
o Unable to tolerate CT scan
o Pregnancy
• Primary outcome:
o Time to AC initiation in patients post ischemic stroke or
TIA due to AF
• Secondary outcomes:
o Type of AC started
o Time to AC initiation if the patient received thrombolytic
therapy at admission
o In-patient recurrent stroke or HT
o Appropriateness of AC on admission and discharge

Small sample size
Initiation time of AC prescribed after discharge was not analyzed
NIHSS score was not always available in the electronic health record
NIHSS score was used as a surrogate measure for stroke severity

Patients were started on AC for secondary stroke prevention
approximately four days following primary stroke/TIA. Early onset of AC
was not associated with a significantly increased risk of hemorrhage.
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Secondary Outcomes

N = 96

Time to AC initiation in pts who received
thrombolytic, days

4.8

In-patient recurrent stroke or HT, n (%)

3 (3)

Appropriateness of AC*
On admission, n (%)
At discharge, n (%)
Excluded from at discharge analysis
Hospice
Expired
*Per the AHA/ACC guidelines

80/96 (83)
81/86 (94)
4 (4)
6 (6)

AC Initiated
Apixaban, n (%)

N = 96
47 (49)

Rivaroxaban, n (%)

3 (3)

Dabigatran, n (%)

2 (2)

Warfarin, n (%)

2 (2)

Enoxaparin, n (%)

1 (1)

Heparin, n (%)

4 (4)

AC initiation deferred to
post-discharge, n (%)

37 (39)
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